Job Stress Combined With Bad Health Habits Lead To Elevated Coronary Artery Disease Risk
redOrbit Staff & Wire Reports - Your Universe Online People with job-related stress who lead unhealthy lifestyles are at nearly double the risk of coronary artery disease compared with people who have work-related stress but lead otherwise...
Latest heart diseases Stories
- Study Presented at the Quality of Care and Outcomes Research 2013 Scientific Session - PALO ALTO, Calif., May 17, 2013 /PRNewswire/ -- CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced results of a clinical utility study of the Corus® CAD gene expression test in the real-world primary care setting for evaluating patients with signs and symptoms suggestive of obstructive coronary artery disease (CAD). The multicenter, prospective study,...
- CAP Accreditation is Awarded to Clinical Laboratories Meeting the Highest Standards of Excellence in Quality Laboratory Practices - PALO ALTO, Calif., May 9, 2013 /PRNewswire/ -- CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced its onsite clinical laboratory has received accreditation from the College of American Pathologists (CAP), which is awarded to facilities that meet the highest standards of excellence in quality laboratory...
-Analysis of Recurrent Heart Failure Hospitalizations in Presence of Informative Censoring - Application of Joint Frailty Model- SAN DIEGO, May 8, 2013 /PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that it will present analysis methods for the MYDICAR development program at an upcoming Conference. The conference "Statisticians in the Pharmaceutical...
SAN DIEGO, May 7, 2013 /PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases announced today it had been selected as a finalist for Red Herring's Top 100 North America award, a prestigious list honoring the year's most promising private technology ventures from the North American business region. Red Herring has been selecting the most exciting and promising start-ups and...
SAN DIEGO, May 2, 2013 /PRNewswire/ -- Cardium Therapeutics (NYSE MKT: CXM) today announced a publication, "Mechanistic, Technical, and Clinical Perspectives in Therapeutic Stimulation of Coronary Collateral Development by Angiogenic Growth Factors", authored by Gabor M Rubanyi, M.D., Ph.D., Cardium's Chief Scientific Officer in the April issue of Molecular Therapy. The publication outlines current scientific knowledge about the mechanistic basis of adaptive coronary collateral...
MINNEAPOLIS, April 29, 2013 /PRNewswire/ -- CVRx, Inc., a private medical device company, announced the first patient enrolled in the Barostim HOPE4HF clinical trial. The study is evaluating the effectiveness and safety of CVRx's Barostim neo in heart failure patients. Dr. Richard Abben, Director of Cardiac Intervention, with the Cardiovascular Institute of the South, in Houma, Louisiana is the Principal Investigator for the center. The prospective, randomized and controlled study...
April Flowers for redOrbit.com - Your Universe Online The American Heart Association (AHA) issued a statement this week that predicts the number of people with heart failure could rise 46 percent – from 5 million in 2012 to 8 million in 2030 – and that the direct and indirect costs to treat heart failure could more than double -- from $31 billion in 2012 to $70 billion in 2030. This means every US taxpayer could be paying $244 a year to care for heart failure patients by 2030. The...
WALTHAM, Mass., April 23, 2013 /PRNewswire/ -- Alere Inc. (NYSE: ALR), a leading provider of near-patient diagnostics and health information solutions, is pleased to announce the final results of the HABIT pilot study, which were recently published in the Journal of the American College of Cardiology. Led by Dr. Alan Maisel, Professor of Medicine at the University of California, San Diego, the study is the first to capture serial data from patients at high risk for recurrent acute...
Silicon BioDevices 'Lab-in-the-Hand' Previewed at 45th Annual Oak Ridge Conference BALTIMORE, April 18, 2012 /PRNewswire/ -- Silicon BioDevices, based in Berkeley, Calif., today presented the results of a pivotal benchmark study of its digital handheld device for high-sensitivity measurement of cardiac troponin-I, a protein found in the heart muscle used to identify heart tissue damage in patients suspected of having a heart attack. The study showed that the totally integrated,...
Treatment that consisted of shock wave (procedure using high-dose ultrasound)-mediated preconditioning of the target heart tissue prior to administration of bone marrow-derived mononuclear cells was associated with significant, albeit modest improvement in left ventricular ejection fraction (a measure of how well the left ventricle of the heart pumps with each contraction) after 4 months in patients with chronic postinfarction heart failure, according to a study in the April 17 issue of JAMA....
Latest heart diseases Reference Libraries
The cardiac stress test is a diagnostic test used in Cardiac pathology for the purpose of patient diagnosis. It measures the heart’s function while placing a heavier workload on the heart. The cardiologist cannot be at the patient’s side while at work, under stress, during a workout or pushed to the limit so this test mimics those activities in a controlled setting. How it is Performed The stress is created by increasing the workload on the cardiac system. This can be accomplished by...
